Association of BMI With Benefit of Metformin Plus Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in Patients With Advanced Lung Adenocarcinoma: A Secondary Analysis of a Phase 2 Randomized Clinical Trial.
rct · Level II
Where this comes from
- Record sourced from PubMed, PMID 35024769.
- Also identified by DOI 10.1001/jamaoncol.2021.7015 and PMC identifier 8759028.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
This secondary analysis reports the survival outcome in patients with <i>EGFR</i> variant-positive non–small-cell lung cancer who had a body mass index that was higher or lower than 24.
Medical subject headings
- Adenocarcinoma of Lung
- Lung Neoplasms
- Metformin